Effects of verapamil combinations with enalapril or indapamide on plasma, vascular and platelet hemostasis and biochemical markers of endothelial dysfunction in patients with arterial hypertension and metabolic syndrome

The combination of verapamil retard and enalapril, or verapamil retard and indapamide SR similarly and significantly increased high-density lipoprotein cholesterol and stable NO2 metabolite levels, reducing platelet aggregation in patients with metabolic syndrome (MS). Compared to the combination of...

Descripció completa

Dades bibliogràfiques

Autors principals:	N. M. Krasnova, T. P. Kalashnikova, A. I. Vengerovsky, E. M. Idrisova, I. V. Kulagina, T. E. Suslova, O. V. Gruzdeva, S. V. Kremeno, N. M. Zheltonogova, A. A. Shishkina, R. S. Karpov
Format:	Artigo
Idioma:	Russo
Publicat:	«FIRMA «SILICEA» LLC 2008-06-01
Col·lecció:	Российский кардиологический журнал
Matèries:	metabolic syndrome arterial hypertension platelet aggregation willebrand factor no2 verapamil enalapril indapamide
Accés en línia:	https://russjcardiol.elpub.ru/jour/article/view/1572
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!